07:00 , Jul 27, 2015 |  BC Week In Review  |  Clinical News

THR-184: Completed Phase II enrollment

Thrasos completed enrollment of 452 patients in the double-blind, placebo-controlled, North American Phase II trial evaluating IV THR-184. Last year, an IDMC recommended that the study proceed with the high-dose arm and drop the 2...
01:34 , Apr 1, 2015 |  BC Extra  |  Financial News

Thrasos raises $21M in series D

Thrasos Therapeutics Inc. (Montreal, Quebec) raised $21 million in a series D round led by new investor BDC Capital and existing investor SR One. Current investors Advanced Technology Ventures; Fonds de solidarite FTQ; Lumira Capital;...
07:00 , Oct 6, 2014 |  BC Week In Review  |  Clinical News

THR-184: Phase II ongoing

Thrasos said an IDMC recommended continuation of a double-blind, placebo-controlled, North American Phase II trial evaluating 3 doses of IV THR-184 based on safety data from 140 patients. The IDMC further recommended that the trial...
07:00 , Mar 13, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Hematology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Hematology Anemia Activin receptor-like kinase 3 (ALK3) Mouse studies suggest inhibiting the bone morphogenetic protein type I receptor ALK3 could help treat anemia. In mice, hepatocyte-specific...
00:59 , Oct 26, 2012 |  BC Extra  |  Financial News

Thrasos raises $35M

Thrasos Therapeutics Inc. (Montreal, Quebec) raised $35 million in a series C round led by new investor SR One. New investors Advanced Technology Ventures; Fonds de solidarite; Lumira Capital; MP Healthcare; and Pappas Ventures joined...
08:00 , Feb 16, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Renal disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Renal disease Renal damage Activin receptor-like kinase 3 (ALK3) In vitro and mouse studies suggest ALK3 agonists could help treat renal damage....
07:00 , Oct 10, 2011 |  BioCentury  |  Product Development

Bone-free BMP

Thrasos Innovation Inc. believes its selective bone morphogenetic protein receptor activators will work for kidney disease because they trigger the BMP pathway's anti-inflammatory, anti-apoptotic and antifibrotic properties, but not its osteogenic properties. BMP has been...
07:00 , Sep 19, 2011 |  BC Week In Review  |  Clinical News

THR-184: Phase I started

Thrasos began a double-blind, placebo-controlled, Canadian Phase I trial to evaluate single and multiple ascending-doses of IV THR-184 in up to 72 healthy volunteers. Thrasos Innovation Inc. , Montreal, Quebec   Product: THR-184   Business:...
07:00 , May 30, 2011 |  BC Week In Review  |  Clinical News

Acceleron preclinical data

In mice that underwent an ovariectomy and were aged to establish bone loss, twice-weekly 10 mg/kg RAP-661, a murine version of ACE-661, significantly increased trabecular bone volume and cortical bone thickness at week 6 vs....